{"id":284235,"date":"2026-07-30T11:09:29","date_gmt":"2026-07-30T11:09:29","guid":{"rendered":"https:\/\/pharmeasy.in\/blog\/?p=284235"},"modified":"2026-07-30T11:43:07","modified_gmt":"2026-07-30T11:43:07","slug":"vaccine-dengue-vaccine-in-india-approval-eligibility-safety-effectiveness","status":"publish","type":"post","link":"https:\/\/pharmeasy.in\/blog\/vaccine-dengue-vaccine-in-india-approval-eligibility-safety-effectiveness\/","title":{"rendered":"Dengue Vaccine in India: Approval, Eligibility, Safety & Effectiveness \u00a0"},"content":{"rendered":"\n\n<\/head>

Table of Contents<\/p>\nToggle<\/span>

Introduction<\/a><\/li>
Is There a Vaccine for Dengue?<\/a><\/li>
Dengue Vaccine Approved in India<\/a><\/li>
How Does the Dengue Vaccine Work?<\/a><\/li>
Who Is Eligible for the Dengue Vaccine?<\/a><\/li>
Dengue Vaccine Dosage Schedule<\/a><\/li>
How Effective Is the Dengue Vaccine?<\/a><\/li>
Is the Dengue Vaccine Safe?<\/a><\/li>
Other Ways to Prevent Dengue<\/a><\/li>
Conclusion<\/a><\/li>
Frequently Asked Questions (FAQs)<\/a><\/li>
References<\/a><\/li><\/ul><\/nav><\/div>\n \n <\/span>\n $\"Join$ \n <\/a>\n
<\/span>Introduction<\/strong><\/span><\/h2>\n\n\n\nDengue is a major mosquito-borne disease in India, with seasonal outbreaks placing a significant burden on public health ^{1<\/sup><\/a>. as cases continue to rise, there is growing interest in effective preventive measures, including vaccination. However, developing a dengue vaccine has been challenging because the disease is caused by four different dengue virus serotypes, all of which need to be addressed for effective protection}^{1<\/sup><\/a>^,<\/sup>}^{2<\/sup><\/a>. \u00a0<\/p>\n\n\n\n}
In recent years, important progress has been made in dengue vaccine development. This blog explores the current status of dengue vaccines in India, including their approval, eligibility, safety, and effectiveness.\u00a0<\/p>\n\n\n\n
<\/span>Is There a Vaccine for Dengue?<\/strong><\/span><\/h2>\n\n\n\nVaccines for dengue have been developed, and some are approved for use in several countries. However, unlike many routine vaccines, dengue vaccines are not universally recommended because their safety and effectiveness can depend on factors such as a person\u2019s age and whether they have had a previous dengue infection. As a result, countries adopt different vaccination policies based on local disease patterns and available evidence ^{3<\/sup><\/a>^,<\/sup>}^{4<\/sup><\/a>.\u00a0<\/p>\n\n\n\n}
Developing a dengue vaccine has been particularly challenging because dengue is caused by four different virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4). Infection with one serotype provides long-term protection only against that specific type, while a later infection with another serotype may increase the risk of severe dengue through a process called antibody-dependent enhancement (ADE). Therefore, an effective vaccine must provide balanced protection against all four serotypes without increasing the risk of severe disease ^{5<\/sup><\/a>^,<\/sup>}^{6<\/sup><\/a>.\u00a0<\/p>\n\n\n\n}
Despite these challenges, global research has made significant progress. \u00a0<\/p>\n\n\n\n
\n
Dengvaxia\u00ae (CYD-TDV) was the first dengue vaccine to receive approval and is recommended only for individuals with confirmed previous dengue infection ^{3<\/sup><\/a>^,<\/sup>}^{7<\/sup><\/a>. \u00a0<\/li>\n\n\n\n}
Qdenga\u00ae (TAK-003) has since been approved in several countries and offers broader protection in eligible populations, although recommendations vary by region ^{7<\/sup><\/a>. \u00a0<\/li>\n\n\n\n}
In addition, several other vaccine candidates, including those from the U.S. National Institutes of Health (TV003\/TV005), the Butantan Institute in Brazil, and some Indian manufacturers, are in advanced stages of clinical development. These ongoing efforts are expected to expand safe and effective vaccination options, particularly for countries like India where dengue remains a major public health concern ^{7<\/sup><\/a>.<\/li>\n<\/ul>\n\n\n}
\n
$\"dengue$ <\/figure><\/div>\n\n\n
<\/span>Dengue Vaccine Approved in India<\/strong><\/span><\/h2>\n\n\n\nIf you are looking for the name of the dengue vaccine approved in India , it is Qdenga, the first dengue vaccine approved in India ^{8<\/sup><\/a>. \u00a0<\/p>\n\n\n\n}
Qdenga is a live, weakened vaccine that helps protect against all four types of the dengue virus. It was developed using recombinant DNA technology, a method that allows scientists to safely modify the virus so it can stimulate the immune system without causing dengue in healthy individuals. The vaccine is manufactured using Vero cells, supplied as a freeze-dried powder, and is mixed with a liquid before being given as an injection under the skin (subcutaneous injection)^{8<\/sup><\/a>.\u00a0<\/p>}
<\/div>